Diabetic Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Diabetic Nephropathy pipeline market research report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.
Key Targets in the Diabetic Nephropathy Pipeline Market
In the Diabetic Nephropathy pipeline market, the key targets are Cannabinoid Receptor 1, Nuclear Factor Erythroid 2 Related Factor 2, Endothelin 1 Receptor, Sodium/Glucose Cotransporter 2, Transforming Growth Factor Beta 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, and C-C Chemokine Receptor Type 2. Cannabinoid Receptor 1 has the highest pipeline products.
Diabetic Nephropathy Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the Diabetic Nephropathy Pipeline Market
The key MoA in the Diabetic Nephropathy pipeline market are Cannabinoid Receptor 1 Antagonist, Endothelin 1 Receptor Antagonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Sodium/Glucose Cotransporter 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, and C-C Chemokine Receptor Type 2 Antagonist. Cannabinoid Receptor 1 Antagonist has the highest pipeline products.
Diabetic Nephropathy Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Diabetic Nephropathy Pipeline Market
The key RoA in the Diabetic Nephropathy pipeline market are oral, intravenous, subcutaneous, parenteral, topical, intraarterial, intravitreal, nasogastric, and ophthalmic. Oral has the highest pipeline products.
Diabetic Nephropathy Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Diabetic Nephropathy Pipeline Market
In the Diabetic Nephropathy pipeline market, the key molecule types are small molecule, monoclonal antibody, cell therapy, synthetic peptide, fusion protein, antisense oligonucleotide, biologic, antisense RNAi oligonucleotide, peptide, recombinant peptide, and recombinant protein. Small molecule has the highest pipeline products.
Diabetic Nephropathy Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Diabetic Nephropathy Pipeline Market
The key companies in the Diabetic Nephropathy pipeline market are AstraZeneca Plc, Boehringer Ingelheim International GmbH, Goldfinch Bio Inc, Scohia Pharma Inc, Serodus ASA, ZyVersa Therapeutics Inc, and Aadi Bioscience Inc. AstraZeneca Plc has the highest number of pipeline products.
Diabetic Nephropathy Pipeline Market, by Companies
To know more about companies, download a free report sample
Market report overview
| Key targets | Cannabinoid Receptor 1, Nuclear Factor Erythroid 2 Related Factor 2, Endothelin 1 Receptor, Sodium/Glucose Cotransporter 2, Transforming Growth Factor Beta 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, and C-C Chemokine Receptor Type 2 |
| Key MoA | Cannabinoid Receptor 1 Antagonist, Endothelin 1 Receptor Antagonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Sodium/Glucose Cotransporter 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, and C-C Chemokine Receptor Type 2 Antagonist |
| Key RoA | Oral, Intravenous, Subcutaneous, Parenteral, Topical, Intraarterial, Intravitreal, Nasogastric, and Ophthalmic |
| Key molecule types | Small Molecule, Monoclonal Antibody, Cell Therapy, Synthetic Peptide, Fusion Protein, Antisense Oligonucleotide, Biologic, Antisense RNAi Oligonucleotide, Peptide, Recombinant Peptide, and Recombinant Protein |
| Key companies | AstraZeneca Plc, Boehringer Ingelheim International GmbH, Goldfinch Bio Inc, Scohia Pharma Inc, Serodus ASA, ZyVersa Therapeutics Inc, and Aadi Bioscience Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
The key targets in the Diabetic Nephropathy pipeline market are Cannabinoid Receptor 1, Nuclear Factor Erythroid 2 Related Factor 2, Endothelin 1 Receptor, Sodium/Glucose Cotransporter 2, Transforming Growth Factor Beta 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, and C-C Chemokine Receptor Type 2.
The types of key MoA in the Diabetic Nephropathy pipeline market are Cannabinoid Receptor 1 Antagonist, Endothelin 1 Receptor Antagonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Sodium/Glucose Cotransporter 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, and C-C Chemokine Receptor Type 2 Antagonist.
The key routes of administration in the Diabetic Nephropathy pipeline market are oral, intravenous, subcutaneous, parenteral, topical, intraarterial, intravitreal, nasogastric, and ophthalmic.
The key molecule types in the Diabetic Nephropathy pipeline market are small molecule, monoclonal antibody, cell therapy, synthetic peptide, fusion protein, antisense oligonucleotide, biologic, antisense RNAi oligonucleotide, peptide, recombinant peptide, and recombinant protein.
The key companies in the Diabetic Nephropathy pipeline market are AstraZeneca Plc, Boehringer Ingelheim International GmbH, Goldfinch Bio Inc, Scohia Pharma Inc, Serodus ASA, ZyVersa Therapeutics Inc, and Aadi Bioscience Inc.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Still undecided about purchasing this report?
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.